Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial

Asian pts with ALK+ advanced/metastatic NSCLC treated with ceritinib 450 mg-fed showed numerically higher efficacy and less GI toxicity compared to 750 mg-fasted pts.